

FOI – 1661

26th May 2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could answer the following two questions:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

• Abatacept [Orencia]	95
• Adalimumab [Humira]	39
• Adalimumab Biosimilars	469

Foi.Team@Southerntrust.hscni.net

• Apremilast [Otezla]	<5
• Baricitinib [Olumiant]	59
• Certolizumab [Cimzia]	78
• Etanercept [Enbrel]	17
Etanercept Biosimilars	177
• Filgotinib [Jyseleca]	0
• Golimumab [Simponi]	78
• Guselkumab [Tremfya]	<5
• Infliximab [Remicade]	<5
• Infliximab Biosimilars	26
• Ixekizumab [Taltz]	38
• Risankizumab [Skyrizi]	0
• Rituximab [MabThera]	0
• Rituximab Biosimilars	110
• Sarilumab [Kevzara]	12
• Secukinumab [Cosentyx]	122
• Tocilizumab [Ro Actemra]	43
• Tofacitinib [Xeljanz]	14
• Upadacitinib [Rinvog]	17
• Ustekinumab [Stelara]	0

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs.

- Adalimumab [Humira]
- Adalimumab Biosimilars
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvog]

****As recorded on the homecare prescriptions that we receive in pharmacy***

• Adalimumab [Humira]	17
• Adalimumab Biosimilars	132
• Certolizumab [Cimzia]	25
• Etanercept [Enbrel]	<5

Foi.Team@Southerntrust.hscni.net

• Etanercept Biosimilars	25
• Golimumab [Simponi]	30
• Infliximab [Remicade]	0
• Infliximab Biosimilars	7
• Ixekizumab [Taltz]	10
• Secukinumab [Cosentyx]	47
• Tofacitinib [Xeljanz]	0
• Upadacitinib [Rinvoq]	<5

Where the response involves low numbers the figure <5 has been provided. This is because releasing the exact figure has the potential to lead to the identification of an individual (s). The Trust has applied Section 40 (2) (third party information) of the Freedom of Information Act 2000 to exempt the exact